Literature DB >> 18411416

NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL.

Maria Luisa Sulis1, Odette Williams, Teresa Palomero, Valeria Tosello, Sasikala Pallikuppam, Pedro J Real, Kelly Barnes, Linda Zuurbier, Jules P Meijerink, Adolfo A Ferrando.   

Abstract

Heterodimerization domain (HD) mutations in NOTCH1 induce ligand-independent activation of the receptor and contribute to the pathogenesis of one-third of human T-cell lymphoblastic leukemias (T-ALLs). Here we report a novel class of activating mutations in NOTCH1 leading to aberrant activation of NOTCH1 signaling in T-cell lymphoblasts. These so-called juxtamembrane expansion (JME) alleles consist of internal duplication insertions in the vicinity of exon 28 of the NOTCH1 gene encoding the extracellular juxtamembrane region of the receptor. Notably, structure-function analysis of leukemia-derived and synthetic JME mutants demonstrated that the aberrant activation of NOTCH1 signaling is dependent on the number of residues introduced in the extracellular juxtamembrane region of the receptor and not on the specific amino acid sequence of these insertions. JME NOTCH1 mutants are effectively blocked by gamma-secretase inhibitors and require an intact metalloprotease cleavage site for activation. Overall, these results show a novel mechanism of NOTCH1 activation in T-ALL and provide further insight on the mechanisms that control the activation of NOTCH1 signaling.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18411416      PMCID: PMC2481531          DOI: 10.1182/blood-2007-12-130096

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  31 in total

1.  Notch1 regulates maturation of CD4+ and CD8+ thymocytes by modulating TCR signal strength.

Authors:  D J Izon; J A Punt; L Xu; F G Karnell; D Allman; P S Myung; N J Boerth; J C Pui; G A Koretzky; W S Pear
Journal:  Immunity       Date:  2001-03       Impact factor: 31.745

Review 2.  Notch signaling in T cell development.

Authors:  M L Deftos; M J Bevan
Journal:  Curr Opin Immunol       Date:  2000-04       Impact factor: 7.486

Review 3.  Notch signaling in lymphopoiesis.

Authors:  Warren S Pear; Freddy Radtke
Journal:  Semin Immunol       Date:  2003-04       Impact factor: 11.130

Review 4.  Notch and cancer: best to avoid the ups and downs.

Authors:  Ivan Maillard; Warren S Pear
Journal:  Cancer Cell       Date:  2003-03       Impact factor: 31.743

5.  A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE.

Authors:  C Brou; F Logeat; N Gupta; C Bessia; O LeBail; J R Doedens; A Cumano; P Roux; R A Black; A Israël
Journal:  Mol Cell       Date:  2000-02       Impact factor: 17.970

6.  A ligand-induced extracellular cleavage regulates gamma-secretase-like proteolytic activation of Notch1.

Authors:  J S Mumm; E H Schroeter; M T Saxena; A Griesemer; X Tian; D J Pan; W J Ray; R Kopan
Journal:  Mol Cell       Date:  2000-02       Impact factor: 17.970

7.  A reassessment of the effect of activated Notch1 on CD4 and CD8 T cell development.

Authors:  B J Fowlkes; Ellen A Robey
Journal:  J Immunol       Date:  2002-08-15       Impact factor: 5.422

8.  Inactivation of Notch1 impairs VDJbeta rearrangement and allows pre-TCR-independent survival of early alpha beta Lineage Thymocytes.

Authors:  Anita Wolfer; Anne Wilson; Mohamed Nemir; H Robson MacDonald; Freddy Radtke
Journal:  Immunity       Date:  2002-06       Impact factor: 31.745

Review 9.  Notch signaling in leukemia.

Authors:  Jon C Aster; Warren S Pear; Stephen C Blacklow
Journal:  Annu Rev Pathol       Date:  2008       Impact factor: 23.472

10.  Differential effects of Notch ligands Delta-1 and Jagged-1 in human lymphoid differentiation.

Authors:  A C Jaleco; H Neves; E Hooijberg; P Gameiro; N Clode; M Haury; D Henrique; L Parreira
Journal:  J Exp Med       Date:  2001-10-01       Impact factor: 14.307

View more
  61 in total

1.  An activating intragenic deletion in NOTCH1 in human T-ALL.

Authors:  J Erika Haydu; Kim De Keersmaecker; Mary Kaye Duff; Elisabeth Paietta; Janis Racevskis; Peter H Wiernik; Jacob M Rowe; Adolfo Ferrando
Journal:  Blood       Date:  2012-04-17       Impact factor: 22.113

Review 2.  Therapeutic approaches to modulating Notch signaling: current challenges and future prospects.

Authors:  Casper Groth; Mark E Fortini
Journal:  Semin Cell Dev Biol       Date:  2012-01-30       Impact factor: 7.727

3.  WT1 mutations in T-ALL.

Authors:  Valeria Tosello; Marc R Mansour; Kelly Barnes; Maddalena Paganin; Maria Luisa Sulis; Sarah Jenkinson; Christopher G Allen; Rosemary E Gale; David C Linch; Teresa Palomero; Pedro Real; Vundavalli Murty; Xiaopan Yao; Susan M Richards; Anthony Goldstone; Jacob Rowe; Giuseppe Basso; Peter H Wiernik; Elisabeth Paietta; Rob Pieters; Martin Horstmann; Jules P P Meijerink; Adolfo A Ferrando
Journal:  Blood       Date:  2009-06-03       Impact factor: 22.113

4.  Structure of the Notch1-negative regulatory region: implications for normal activation and pathogenic signaling in T-ALL.

Authors:  Wendy R Gordon; Monideepa Roy; Didem Vardar-Ulu; Megan Garfinkel; Marc R Mansour; Jon C Aster; Stephen C Blacklow
Journal:  Blood       Date:  2008-12-15       Impact factor: 22.113

5.  The NOTCH signaling pathway: role in the pathogenesis of T-cell acute lymphoblastic leukemia and implication for therapy.

Authors:  Valeria Tosello; Adolfo A Ferrando
Journal:  Ther Adv Hematol       Date:  2013-06

Review 6.  Hypoxia, notch signalling, and prostate cancer.

Authors:  Laure Marignol; Karla Rivera-Figueroa; Thomas Lynch; Donal Hollywood
Journal:  Nat Rev Urol       Date:  2013-05-28       Impact factor: 14.432

Review 7.  The role of NOTCH1 signaling in T-ALL.

Authors:  Adolfo A Ferrando
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

Review 8.  Mechanisms and clinical prospects of Notch inhibitors in the therapy of hematological malignancies.

Authors:  Yulia Nefedova; Dmitry Gabrilovich
Journal:  Drug Resist Updat       Date:  2008-10-31       Impact factor: 18.500

9.  Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and gamma-secretase inhibitors.

Authors:  Ana Silva; Patrícia Y Jotta; André B Silveira; Daniel Ribeiro; Silvia R Brandalise; J Andrés Yunes; João T Barata
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

Review 10.  Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia.

Authors:  Teresa Palomero; Adolfo Ferrando
Journal:  Clin Lymphoma Myeloma       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.